147 related articles for article (PubMed ID: 28839525)
1. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2017; 5(1):1355203. PubMed ID: 28839525
[No Abstract] [Full Text] [Related]
2. The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.
Jørgensen J; Servos S; Kefalas P
J Mark Access Health Policy; 2018; 6(1):1500419. PubMed ID: 30364868
[No Abstract] [Full Text] [Related]
3. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
Michelsen S; Nachi S; Van Dyck W; Simoens S; Huys I
Front Pharmacol; 2020; 11():594446. PubMed ID: 33363468
[No Abstract] [Full Text] [Related]
4. A Budget Impact Analysis of Gene Therapy for Sickle Cell Disease: The Medicaid Perspective.
DeMartino P; Haag MB; Hersh AR; Caughey AB; Roth JA
JAMA Pediatr; 2021 Jun; 175(6):617-623. PubMed ID: 33749717
[TBL] [Abstract][Full Text] [Related]
5. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies.
Horrow C; Kesselheim AS
Health Aff (Millwood); 2023 Nov; 42(11):1532-1540. PubMed ID: 37931198
[TBL] [Abstract][Full Text] [Related]
6. Accelerating patient access to oncology medicines with multiple indications in Europe.
Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
[No Abstract] [Full Text] [Related]
7. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
8. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
9. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
10. Gene therapies: the challenge of super-high-cost treatments and how to pay for them.
Carr DR; Bradshaw SE
Regen Med; 2016 Jun; 11(4):381-93. PubMed ID: 27185544
[TBL] [Abstract][Full Text] [Related]
11. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
[TBL] [Abstract][Full Text] [Related]
12. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
[TBL] [Abstract][Full Text] [Related]
13. Critical Reflections on Reimbursement and Access of Advanced Therapies.
Simoens S; De Groote K; Boersma C
Front Pharmacol; 2022; 13():771966. PubMed ID: 35662719
[No Abstract] [Full Text] [Related]
14. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
15. Approaches to manage 'affordability' of high budget impact medicines in key EU countries.
Flume M; Bardou M; Capri S; Sola-Morales O; Cunningham D; Levin LA; Postma MJ; Touchot N
J Mark Access Health Policy; 2018; 6(1):1478539. PubMed ID: 29915664
[No Abstract] [Full Text] [Related]
16. Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.
Kefalas P; Ali O; Jørgensen J; Merryfield N; Richardson T; Meads A; Mungapen L; Durdy M
J Mark Access Health Policy; 2018; 6(1):1511679. PubMed ID: 30151078
[No Abstract] [Full Text] [Related]
17. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
18. Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®).
Callenbach MHE; Schoenmakers D; Vreman RA; Vijgen S; Timmers L; Hollak CEM; Mantel-Teeuwisse AK; Goettsch WG
Value Health; 2024 May; ():. PubMed ID: 38795960
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
